Trials / Unknown
UnknownNCT05225831
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in Patients With R/R B-Cell Acute Lymphoblastic Leukemia
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, single-arm, prospective clinical study to evaluate the safety and efficacy of anti CD19 and CD22 CAR-T cell in the treatment of R/R B-ALL.
Detailed description
CD19-directed CAR-T cell therapy has shown promising results in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. CD19 and CD22 are proteins usually expressed on the surface of the B leukemia cells. The dual-CARs enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous CD19/CD22 Chimeric Antigen Receptor T-cells | A single infusion of CD19 and CD22 CAR-T cells. |
| DRUG | Cyclophosphamide,Fludarabine | Given |
Timeline
- Start date
- 2021-08-15
- Primary completion
- 2023-08-01
- Completion
- 2023-11-01
- First posted
- 2022-02-07
- Last updated
- 2022-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05225831. Inclusion in this directory is not an endorsement.